Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Executive Summary
Amgen and Johnson & Johnson are no longer able to promote the impact of their respective erythropoiesis-stimulating agents Aranesp and Procrit on symptoms of anemia in cancer patients, FDA said
You may also be interested in...
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling
FDA and the sponsors of erythropoiesis-stimulating agents were mostly able to reach an agreement on safety revisions to labeling of the anemia therapies, but the agency was forced to employ its new regulatory authority to resolve a couple points of continued disagreement
Amgen, J&J Propose New Target Range For Aranesp, Procrit
Just a year after FDA removed information related to a dosing target range for erythropoiesis-stimulating agents from product labeling, Amgen and Johnson & Johnson are proposing to re-establish a specific hemoglobin target range for the anemia therapies